Predictors of DMPA-SC continuation among urban Nigerian women: the influence of counseling quality and side effects

Jenny Liu a,⁎, Jennifer Shen b, Nadia Diamond-Smith c

a Institute for Health and Aging, Department of Social and Behavioral Sciences, School of Nursing, University of California, San Francisco, 3333 California Street, Suite 340, San Francisco, CA 94118, USA
b Institute for Health Policy Studies, School of Medicine, University of California, San Francisco, 3333 California Street, Suite 2660, San Francisco, CA 94101, USA
c Global Health Sciences, Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, 530 16th Street Mission Hall, San Francisco, CA 94158, USA

ARTICLE INFO

Article history:
Received 18 December 2017
Received in revised form 18 April 2018
Accepted 20 April 2018

Keywords:
Depot medroxyprogesterone acetate (DMPA)
Subcutaneous injection
Contraception
User experience
Side effects
Continuation

ABSTRACT

Objectives: In 2015, private healthcare providers in Nigeria introduced DMPA-SC (depot medroxyprogesterone acetate administered subcutaneously) into the method mix. We aimed to [1] examine the sociodemographic predictors of continued DMPA-SC use after 3 months, and [2] characterize the additional influences of contraceptive counseling quality and experiences of side effects on continuation.

Study design: From March to August, 2016, we conducted phone interviews with a convenience sample of women obtaining DMPA-SC from selected providers to survey them about their experience obtaining an initial dose of DMPA-SC. Study coordinators contacted women again about 3 months later after they were due for reinjection. We used logistic regressions to examine the likelihood of having obtained a subsequent dose of DMPA-SC at follow-up as predicted by sociodemographic characteristics, a quality of counseling indicator based on responses to a 14-item scale, and reports of side effects experienced.

Results: Of the 541 DMPA-SC users who completed the first survey, 311 were reached again via phone after 3 months to conduct a second survey. Multivariate results for sociodemographic predictors of continued DMPA-SC use show that those with some college education or more (OR=2.79; 95% CI: 1.09–7.14), and those with four or more children (OR=2.89; 95% CI: 1.09 0.767) were more likely to obtain another dose. Our summary quality measure showed that women overall rated the quality of their initial counseling session high. Logistic regressions indicated that higher quality during the initial counseling session is related to the likelihood of getting another dose of DMPA-SC (OR=2.04; 95% CI: 1.12–3.47) whereas experiencing more bleeding reduced the likelihood of continuation after 3 months (OR=0.15; 95% CI: 0.07–0.34).

Conclusions: Among urban Nigerian women, both counseling quality and experiences of side effects were important factors in predicting continued use of DMPA-SC after 3 months. These findings are consistent with previous studies of DMPA and injectable contraception continuation.

Implications: New contraceptive methods that are designed for increased access and ease of use, combined with high quality provision, have potential to increase contraceptive use in settings with low levels of contraceptive prevalence. Higher quality counseling can help encourage women’s continuation of a new injectable contraceptive method at 3 months.

© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Effective family planning requires contraceptive adherence. However, due to a variety of factors—cost, convenience, method dissatisfaction, experiences of side effects, partner disapproval, and limited method options—many women discontinue contraception, which contributes to high rates of unwanted fertility and overall fertility [1–4]. Researchers and family planning practitioners alike believe quality of contraceptive counseling and care is critically important for method continuation [5]. High quality providers may be better equipped to give contraceptive counseling, and may be more effective at informing women of potential side effects, thereby increasing the likelihood that women manage or tolerate these experiences and continue with their method.

Although many studies have explored the relationship between quality of care and rates of discontinuation, the empirical evidence supporting this hypothesis remains inconclusive. A study across 15 countries showed that between 7 and 27% of women discontinued contraception because of poor service quality [6]. Improvements in the quality of care at health centers, either engendered through policy
changes, as seen in Senegal [7], or through health worker training programs incorporating special emphases on contraceptive counseling, such as in Kenya [8], have led to increased contraceptive continuation among women. Such improvements may have influenced clients' perceptions of quality of care, which is associated with continued contraceptive use, as found in Bangladesh [9]. However, in Peru, no significant differences in continuation rates were found between a cohort that received family planning counseling from providers trained on a jobs-aid assisted counseling style and a control cohort [10]. Similarly, in the Philippines, a longitudinal family planning provider program was implemented but did not lead to any significant effects on family planning outcomes [11].

Furthermore, each contraceptive method has unique features which also influence the likelihood of method and contraceptive continuation. Ali et al. report method-specific discontinuation probabilities across 19 Demographic and Health Survey (DHS) countries, and find 12-month discontinuations rates of 50.4% for condoms, 43.5% for the pill, 40.6% for injectables, and 13.1% for IUDs amid an overall rate of 37.7% [3]. In both developed and developing country contexts, IUDs have the highest continuation rates compared to other methods, possibly due to higher costs of removal associated with the method [12–15].

Since 2014, a new, easy-to-administer, all-in-one, 3-month DMPA-subcutaneous (DMPA-SC; i.e., Sayana Press® formulation for depot medroxyprogesterone acetate) contraceptive injectable has been introduced in more than 14 countries, including Nigeria. DMPA-SC is a low-dose formulation of DMPA (104-mg/0.65 ml), with slower rate of absorption and equivalent efficacy, as well as high patient satisfaction [16]. Many hypothesized that DMPA-SC would be a 'game changer' [17] for increasing access to contraception in low resource settings because of its potential for home- and self-injection and ease of use [18], with cohort-studies in Senegal showing the feasibility of self-injection [18]. Recent studies show that discontinuation rates of self-administered DMPA-SC were not different and even reduced compared to provider-administered DMPA-IM (i.e., DMPA-intramuscular; e.g., Depo Provera) [19–21]. Yet, little is known about other predictors of adherence to DMPA-SC, including quality of care and experiences of side effects.

Compared to IUDs and other long-term methods, continuation of injectable contraceptives is more difficult to maintain. Even as injectable contraceptives are gaining popularity in low-resource settings [22–24], especially for young women [25], continuation on injectable contraception is low in many settings [26,27]; discontinuation typically occurs within one year with estimated rates of up to 77%, and particularly high rates of drop-off observed after the first and second injections [3,26,28,29]. In one study in Nigeria, more than 50% of sampled women using DMPA-IM did not continue within one year [30]. The most frequently cited reasons for discontinuation were incompatibility with using a specific method, side effects, and desire for pregnancy [3,27]. For DMPA-SC, emerging evidence shows that reasons for discontinuation include late injection, access challenges/stockouts, partner disapproval, irregular bleeding and weight changes [20,31]. However, from studies in the U.S., China, Mexico, and South Africa, women who received more intensive structured counseling, including discussion about side effects, were more likely to continue DMPA use [26,32–34], suggesting that the inclusion of side effects within contraceptive counseling can be one way to encourage method continuation.

In the current study, we use data collected during the introduction of DMPA-SC in Nigeria to examine DMPA-SC users' decision to continue on the method. DMPA-SC was introduced into the market in Nigeria in 2015 as part of larger efforts to increase method offerings and overall access to contraception. Although modern contraceptive use among all women in Nigeria is extremely low (11% in 2013), after condoms, injectables are the most popular method among current users, accounting for 23% of modern methods used [35]. For the purposes of monitoring and evaluation of the DMPA-SC introductory program in Nigeria, we collected data on DMPA-SC users obtaining the product from selected private sector providers in seven South West states where the program was first introduced. Private providers included for-profit clinics, maternity homes, pharmacies, patent and proprietary medicine vendors, and individually practicing clinicians (e.g., physicians, nurses/midwives). The overall findings and lessons learned from this effort, including detailed accounting of data collection methods, are reported elsewhere [36].

In this study, we examined users' responses to two phone surveys conducted 3–5 months apart to [1] assess the sociodemographic predictors of continued DMPA-SC use at 3 months, and [2] characterize the additional influences of contraceptive counseling quality and experiences of side effects on continued DMPA-SC use. Although our convenience sample of women is primarily from urban areas, this is the first study to empirically assess whether socioeconomic and demographic backgrounds, as well as quality of family planning counseling, are predictors of DMPA-SC continuation among consumers at large obtaining the product from an array of private sector providers that dominate the provision of contraceptive products in Nigeria [31]. Since this study was not conducted in a controlled setting, our results may help inform how future scaled DMPA-SC programs may better serve their broad base of clients under real world conditions.

2. Materials and methods

2.1. Data collection

Between March and June 2016, we recruited healthcare providers across seven South West states (Ekiti, Kwara, Lagos, Ogun, Ondo, Osun, Oyo). The product's distributor, a contraceptive social marketing firm primarily supplying private sector providers, generated a list of 358 providers that had purchased DMPA-SC, including hospitals/clinics, retail drug outlets, and licensed Community Health Extension Workers (CHEWs) hired and trained to conduct proactive community-based distribution. After an initial cleaning of the provider list and eliminating providers with missing or incorrect data, we attempted to contact 316 providers for participation. Provider participation was entirely voluntary, and providers who consented were offered 1000 Naira (~US$5.00) in mobile phone credits in return for participation. In total, 205 providers consented to participate, of which 50% were from Lagos and 21% from Oyo; by profession, over 40% were nurses or midwives, and about 30% were CHEWs. Participating providers were asked to assist in the recruitment of DMPA-SC users by recording the names and phone numbers of customers who purchased an injectable contraceptive (of any type) and identifying customers who agreed to be contacted for a phone survey.

Of 1423 women listed in providers' registers, 1179 purchased DMPA-SC. We called all DMPA-SC customers who consented to be contacted (N=994) to complete an initial survey administered by a trained, bilingual (in Yoruba, the dominant local language) interviewer over the phone, lasting 15–20 min, and compensated with 200 Naira (~US$0.57) of mobile phone credits. Of the 944 women called, 541 women completed the initial phone survey about their recent experience obtaining a dose of DMPA-SC; 374 women were not able to be reached after up to five attempts, 33 refused to participate, 22 were not eligible, and 24 phone numbers were incorrect. About half (N=266; 49.6%) were contacted within one month of their injection, 32.6% (N=175) were contacted within 2 months, 16.0% (N=86) within 3 months, and 1.7% (N=9) within 4–5 months.1 About 3 months later, timed for after respondents were due for a reination (range 2.2–5.6 months; median 4.7 months), all 541 respondents who verbally consented to be contacted again during the initial phone survey were called to complete a second phone survey about care-seeking for a subsequent dose of DMPA-SC. During the follow-up call, women were again verbally consented to participate before conducting the survey (about 5–10 min) and compensated with 100 Naira (~US$0.29) of mobile phone credits. Of the 342 women completing a second follow-up phone survey, the 311 women who

1 An additional five women did not respond to the question of how long ago they received their injection.
answered all quality measure items were included in this analysis. Fig. 1 displays the recruitment and longitudinal follow-up of women in the study.

2.2. Quality measures

The first survey round included questions on three different aspects of quality (see Table 1): information given, interpersonal communications, and choice of method. These quality measures were based on the domains outlined in the Bruce-Jain framework, and informed by items used by subsequent researchers measuring various domains of the quality of family planning services [37,38]. After collating quality measures employed by different contraception studies [5,39,40], we selected 16 items that covered the three quality domains in this study. These questions were pre-tested in February 2016 with women who had been administered DMPA-SC during outreach events held by the product’s

Fig. 1. Participant recruitment, survey, and interview. Of 1423 women listed in providers’ registers, 1179 purchased DMPA-SC, and all DMPA-SC customers who consented to be contacted for a survey (N=994) were called to complete an initial survey. Of 541 women completing the initial phone survey about their recent experience obtaining a dose of DMPA-SC, all verbally consented to be contacted again to complete a second phone survey about care-seeking for a subsequent dose of DMPA-SC. Of the 342 women completing a second follow-up phone survey, the 311 women who answered all quality measure items were included in this analysis.
supplier and who verbally consented to be contacted for a phone survey. During the pre-test, we aimed to assess women’s comprehension over the phone, completion time, and response fatigue. Primarily due to reasons of poor phone connection quality, which compromised user comprehension, and respondent fatigue, we chose to restrict response options to binary choices (i.e., “yes” or “no”) to the extent possible; categorical responses were retained for two items (see below).

To construct summary quality measures for analysis, we excluded two items that were asked in the survey under interpersonal communications (i.e., “Did you feel the provider treated you respectfully?” and “Do you believe that the information that you shared about yourself with the provider will be kept confidential?”) because all women responded positively, thus yielding no variation for analysis. For all quality items, we constructed a binary indicator for the participant’s affirmative response to the positive quality outcome, which was then summed across all items to create a composite continuous summary measure (range 0–14). For non-binary quality items of providers’ preference for the choice of method (none, slight, moderate, or strong) and information given (too little, just right, too much), we categorized the responses into a binary variable. Based on findings from previous studies of patient preferences for shared and informed decision-making, providers perceived to have no or slight preference for the choice of method were considered to be indicative of higher quality than those perceived to have had a moderate or strong preference [41]. Similarly, the level of information that was perceived to be “just right” was considered to be indicative of higher quality than either “too much” or “too little.”

Based on the resulting distribution of the summary measure, we then created a dummy variable indicator for “high quality.” As has been done in other studies involving quality of care indices [42], we use the median quality score as the cutoff for “higher quality” versus “low quality. In our case, “high quality” is defined as a summary score greater than or equal to the median value of 12, the threshold at which a large jump is also observed in the cumulative distribution of the quality summary score (see Fig. 2). Quality summary scores of 12 or above comprised 44.7% of the sample.

2.3. Side effects

In the follow-up survey round, all respondents were asked if they had experienced side effects associated with the injection. Respondents could report multiple side effects if relevant. Among the 304 women who responded to this question, we separated these responses into four categories to include as predictors in the multivariate regression: no side effects experience, less/no bleeding, more bleeding, and all others (which included responses such as headaches, nausea, or dizziness, weight gain or loss, fatigue, fever, malaria, upset stomach, and unspecified general body reactions).

2.4. Outcome: Continuation of DMPA-SC

In the follow-up survey round, we asked women if they had obtained another dose of DMPA-SC since the time of the first phone survey. We constructed a dummy variable to indicate self-reported continued use for those who reported obtaining another dose; all others who did not obtain another dose since the first phone survey, including those who stated their intent to do so, were categorized as not continuing DMPA-SC use.

2.5. Data analysis

We conducted multivariate analyses using logistic regression to predict DMPA-SC continuation with our quality measures and individual background characteristics (i.e., age, marital status, education, religion, parity, wealth quintile,2 state of residence, type of provider where the initial dose of DMPA-SC was purchased, and whether the woman had previously used some form of modern contraception prior to initiating DMPA-SC). Standard errors were corrected for heteroskedasticity and clustered by provider to account for autocorrelation among women attending the same provider.

2.6. Ethics statement

The Institutional Review Board at the University of California, San Francisco (IRB# 15–18,353) and the Nigeria Health Research Ethics Committee (NHREC/01/01/2007–06/01/2016) approved this research.

3. Results

3.1. Sample characteristics

Our convenience sample of DMPA-SC users (N=311; Table 1) primarily comprised of married (97.1%) women aged 25 or older (55.6% 25–34; 37.0% 35+) with secondary (58.2%) or college/university (28.3%) schooling and at least two children (86.2%). Nearly 70% were in the wealthiest quintile, and 66% obtained their initial DMPA-SC dose from a CHEW conducting proactive community-based distribution. Approximately 75% of women were from three states—Lagos, Ogun, and Oyo—which encompassed the main urban centers in the region. Our analysis of attrition found that women who were lost to follow-up were significantly more likely to be younger, unmarried, and have fewer children (see Supplementary Table S1). Of those included in the follow-up survey, 49.7% of women had obtained another dose of DMPA-SC.

3.2. Quality measure

Table 1 summarizes the items included our quality measure. Positive responses across quality items were nearly all high with two exceptions in the domain of method choice. Only 3.7% reported that the provider

| Table 1 |
| --- |
| Quality items and summary measures (N=311). |
| Items | Positive responses n | % |
| Information given |
| Provider asked if you had ever used contraception before | 283 | 91.1% |
| Provider asked if you had ever experienced any side effects from another contraceptive | 271 | 87.1% |
| Provider asked you wanted to have more children in the future | 278 | 89.4% |
| Provider asked if you had any health issues (e.g., infections, high blood pressure) | 237 | 76.2% |
| Provider described possible side effects of DMPA-SC | 230 | 74.0% |
| Provider told you what to do if you had problems with DMPA-SC | 231 | 74.3% |
| Provider told you how long it protects against pregnancy | 310 | 99.7% |
| Provider asked if you were pregnant/did anything to find out if you were pregnant | 284 | 91.4% |
| Interpersonal |
| Felt comfortable to ask questions | 310 | 99.7% |
| Have enough privacy during the visit | 300 | 96.5% |
| Felt that the waiting time was reasonable | 276 | 88.7% |
| Provider had no or slight preference for which method you should use (vs. moderate/strong preference) | 10 | 3.2% |
| Felt that the information given to you was just right (vs. too little too much) | 304 | 97.7% |
| Provider mentioned methods other than DMPA-SC | 141 | 45.3% |
| Summary measures |
| Summary score (range: 0–14) mean [SD] | 11.1 | [1.76] |
| High quality indicator (score ≥ median 12) | 176 | 56.6% |

2 Because our sample is predominantly urban, we apply the urban asset weight index to yield a wealth distribution comparable to the Nigeria national distribution for urban areas per the Nigeria Demographic and Health Survey 2013 [35], following methods developed by Chakroborty et al. [43].
had no or little preference for which method she should choose. In addition, 45.3% reported that the provider mentioned a contraceptive method other than DMPA-SC. Our analysis of attrition also found that responses for women who were lost to follow-up were not significantly different from those women completing the follow-up survey for each quality item (see Supplementary Table S2). When summing across all items, the mean score was 11.1 with 56.6% registering a score greater than or equal to the median of 12. The Cronbach’s alpha for the summary score was 0.63.

3.3. Side effects

Fig. 3 shows the side effects that women reported experiencing. About half of respondents reported not experiencing any side effect

Fig. 2. Cumulative distribution of the summary quality measure. Dummy variables indicating the higher quality outcome for all 14 item measures were summed to create a continuous quality index (range 0–14). Based on the resulting distribution of the summary index, we then created a dummy variable indicator for “high quality.” As has been done in other studies involving quality of care indices [42], we use the median quality score as the cutoff for “higher quality” versus “low quality. In our case, “high quality” is defined as a summary score greater than or equal to the median value of 12, the threshold at which a large jump is also observed in the cumulative distribution of the quality summary score. Quality summary scores of 12 or above comprised 44.7% of the sample.

Fig. 3. Side effects experienced. About half of respondents reported not experiencing any side effect (50.0%) while 28.6% indicated that they had less or no bleeding and 16.1% reported more bleeding. A small number of women reported headaches, nausea, or dizziness (1.6%), changes in weight (2.6%), and a variety of other side effects (2.6%).
suggests that, even in scenarios where women rate the overall quality of care as relatively high, small differences in the quality of care at the time of method uptake can influence contraceptive continuation. In this population, the lowest quality ratings were for items related to method choice: only a few women reported that their providers had little or no preference for which method she chose and about half were offered DMPA-SC as the only choice. The lack of method choice may be a result of providers being recently introduced to and/or trained on DMPA-SC, and thus more likely to promote it as a new product to the exclusion of other methods.

The strong association of the summary quality score with continued DMPA-SC use despite the limited variation in this overall quality measure also suggests that our conception of what constitutes “high quality” counseling in this setting may require further thought. This may be particularly true in terms of interpersonal dynamics, which were the highest-rated items within our quality measure. It is difficult to disentangle what type of “quality” the indicator for “how involved the provider was in decision making” is indicative of in the Nigerian setting. On the one hand, in a “Western” quality framework, researchers and practitioners may place high value on women’s ability to make an informed decision and not be pressured by a provider [8]. Past studies in the United States exploring how involved women would like their provider to be in decision making about a method have found that women wanted the decision-making process to center around their preferences, although there were notable differences in how involved women wanted their provider to be by racial/ethnic group [44]. However, it is possible that in the Nigerian setting women may prefer to have the provider give more direction, particularly among lower-educated populations, in the absence of access to more information, and within sociocultural norms that defer decision-making to authoritative figures. Furthermore, one could argue that it is the provider’s role to suggest a method that they think is most appropriate for a certain individual given their expertise. Indeed, many women in our sample stated that they highly valued the providers’ recommendation as one of the main reasons why they chose to have the injection [36]. However, this assumes that providers are not unduly influenced by other incentives or the novelty and recent training on DMPA-SC to suggest one method over another.

Similarly, that the vast majority of the quality indicators had over 90% of women reporting “high” quality again suggests that these questions might not be appropriate for capturing heterogeneity in women’s experiences of quality within this population. Past studies also found very positive responses to similar measures, which suggests that these measures may not be universally relevant or salient. Recent research in India and Kenya found that women value different aspects of quality of care for contraception than are often included in international measures. For example, waiting long periods of time was acceptable to

### Table 2
Sample characteristics and sociodemographic predictors of continued DMPA-SC use.

| Age | N=311 | % Continued DMPA-SC |
| --- | --- | --- |
| <25 | 23 | 7.4% |
| 25–34 | 173 | 55.6% |
| 35+ | 115 | 37.0% |

| Marital status | N=311 | % Continued DMPA-SC |
| --- | --- | --- |
| Not currently married | 9 | 2.9% |
| Currently married | 302 | 97.1% |

| Religion | N=311 | % Continued DMPA-SC |
| --- | --- | --- |
| Muslim | 97 | 31.2% |
| Christian | 214 | 68.8% |

| Parity | N=311 | % Continued DMPA-SC |
| --- | --- | --- |
| 0–1 children | 43 | 13.8% |
| 2 children | 75 | 24.1% |
| 3 children | 94 | 30.2% |
| 4+ children | 99 | 31.8% |

| Wealth quintile | N=311 | % Continued DMPA-SC |
| --- | --- | --- |
| Poorest, poor, medium wealth | 32 | 10.3% |
| Wealthy | 63 | 20.3% |
| Very wealthy | 216 | 69.5% |

| contraceptive use | N=311 | % Continued DMPA-SC |
| --- | --- | --- |
| New user | 89 | 28.6% |
| Switched from a traditional method | 47 | 15.1% |
| Switched from another injectable | 102 | 32.8% |
| Switched from a non-injectable modern method | 73 | 23.5% |

| Place of purchase | N=311 | % Continued DMPA-SC |
| --- | --- | --- |
| Private hospital/clinic/provider | 43 | 13.8% |
| Retail drug outlet | 29 | 9.3% |
| DKT Bee | 205 | 65.9% |
| Government hospital/clinic | 34 | 10.9% |
| State | 220 | 70.7% |
| All other states | 91 | 29.3% |

Robust standard errors in parentheses, clustered by provider.
*** p<.01, ** p<.05, * p<.1.

(50.0%) while 28.6% indicated that they had less or no bleeding and 16.1% reported more bleeding. A small number of women reported headaches, nausea, or dizziness (1.6%), changes in weight (2.6%), and a variety of other side effects (2.6%).

### 3.4 Regression results

Multivariate results for sociodemographic predictors of continued DMPA-SC use (Table 2) showed that those with some college education or more (OR=2.794; 95% CI: 1.093–7.140), and those with four or more children (OR=2.888; 95% CI: 1.087–7.668) were more likely than their less educated and lower parity counterparts to oobod of getting another dose to their another dose. When quality and side effects were added as predictors, each had an independent effect on predicting continuation (Table 3). Having a higher quality initial provider interaction was significantly associated to the likelihood of getting another dose of DMPA-SC at 3 months (OR=2.039; 95% CI: 1.120–3.472). However, experiencing more bleeding reduced the likelihood of DMPA-SC continuation at 3 months (OR=0.154; 95% CI: 0.153–1.173).

### 4. Discussion

#### 4.1. Main findings

Our findings indicate that higher quality of care at the time of initial counseling is associated with continuing DMPA-SC after 3 months.
some women in Kenya, while some women in India felt that having other patients in the room during exams was acceptable privacy [38]. Additional qualitative research is needed to further understand the meaning of quality to women in the Nigerian context.

Although over 70% of respondents indicated that the provider had asked or informed her about experiences with side effects, these aspects of information given were rated relatively lower in quality compared to other item responses and domains. Correspondingly, many women (60%) reported side effects, especially irregular bleeding, as the main reason they discontinued DMPA-SC, which is consistent with other studies in Nigeria on the influence of side effects on continuing a variety of different methods, as well as studies of DMPA-related side effects and continuation [33,34,45]. However, it should be noted that women in our study were only surveyed after two injections spanning up to 6 months of protection against pregnancy; this short follow-up time frame may not have been sufficient for many women to experience side effects associated with long-term use of DMPA, such as amenorrhea [46]. Nonetheless, our results suggest that there is still much room for improvement in counseling quality, particularly on explaining side effects—whether experienced in the past or anticipated in the future—and that such improvements could have a large effect on DMPA-SC continuation.

4.2. Limitations

Our convenience sample of DMPA-SC users is unlikely to be representative of the Nigerian population of reproductive age women. In particular, due to lack of existing patient data from private sector providers and the challenges of systematically collecting such information, a representative sampling frame was not possible. Our sample was predominantly urban and only residing in the seven South West states; these women are likely to be wealthier and more educated than their national counterparts. As such, the examination of continuation is restricted to the subset of women who completed both surveys, who were more likely to be older and married compared to the full set of respondents to the baseline survey. While analyses of quality items between the follow-up cohort and those lost to follow-up did not show significant differences in responses across all item responses (see Supplementary materials), it should be recognized that younger, unmarried women nonetheless generally experience worse quality than older, married women [47]. Women were also only asked a small number of questions related to quality, which might not necessarily reflect their own perceptions of what constitutes quality for contraceptive services. Additional research is needed to define quality within specific populations. Participants’ answers to the quality questions could be biased due to poor recall or social desirability, particularly if they suspected their responses to somehow be relayed back to the provider. It is also possible that providers only listed the contacts of certain types of clients that they thought would give good reports; however, we think this risk is low because providers did not know the nature of the survey for clients. While we trained interviewers to emphasize confidentiality for all providers and users, we cannot rule out these sources of potential bias. Finally, the current analysis only follows respondents for a short period after their initial dose and resource constraints prevented continued follow-up, even for women who stated that they intended to obtain a DMPA-SC reinjection at the time of the follow-up survey. Further analysis is needed to understand how quality is associated with continuation over longer time periods.

4.3. Conclusion

Contraceptive use remains low in Nigeria, and understanding how to increase method continuation is vital. While there is increasing focus on the effect of counseling quality on uptake and continuation, study results have been mixed. Our results support the notion that higher quality counseling can encourage women’s continuation of a new injectable contraceptive method at 3 months. It also highlights the substantial role that side effects can have on women’s decision to continue using a method. Future programs could focus on improving the quality of counseling about side effects, and particularly those related to bleeding (e.g., supporting women through their experience of side effects rather than relying on a brief mention during initial counseling) as this may help women expect and understand certain side effects and thus not be as likely to discontinue their method. New contraceptive methods designed for increased access and ease of use, combined with high quality provision, have potential for increased contraceptive use in settings with low contraceptive prevalence.

Acknowledgments

The authors would like to thank the data collection team at Akena Associates, Nigeria, for their excellent work in the field. Additional in-kind and operational support from DKT Nigeria is gratefully acknowledged.

Funding

This work was supported by the Bill & Melinda Gates Foundation, Seattle, WA [grant number OPP1133271] and the Children’s Investment Fund Foundation, London, UK [grant number N/A]. Program officers from these Foundations contributed to the overall objectives of the research portfolio and provided feedback on research protocols and instruments. However, the authors had sole responsibility and authority for the collection, analysis and interpretation of data, the writing of the report, and in the decision to submit this article for publication.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.contraception.2018.04.015.

References

[1] Blanc AK, Curtis S, Croft T. Does Contraceptive Discontinuation Matter?: Quality of Care and Fertility Consequences [Internet]. United States Agency for International Development (USAID); 1999 Sep. (MEASURE Evaluation Project). Report No. WP-99-14. Available from: https://www.measureevaluation.org/resources/publications/wp-99-14. [2] Ali M, Cleland J. Determinants of contraceptive discontinuation in six developing countries. J Biosoc Sci 1999;31(3):345–60.
[3] Ali MM, Cleland J, Shah H. Causes and consequences of contraceptive discontinuation: Evidence from 60 demographic and health surveys. World Health Organiza­tion; 2012.
[4] Ali M, Cleland J. Contraceptive discontinuation in six developing countries: a cause­specific analysis. Int Perspect Sex Reprod Health 1995;21(3).
[5] Dehendorf C, Henderson JT, Vittinghoff E, Grumbach K, Levy K, Schmitt­diel J, et al. Association of the quality of interpersonal care during family planning counseling with contraceptive use. Am J Obstet Gynecol 2016;215(1):78.e1­9.
[6] Blanc AK, Curtis SL, Croft TN. Monitoring contraceptive continuation: links to fertility outcomes and quality of care. Stud Fam Plann 2002;33(2):127­40.
[7] Sanogo D, RamalRao S, Jones H, N’Diaye P, Mbow B, Diop CB. Improving quality of care and use of contraceptives in Senegal. Afr J Reprod Health 2003;7(2):57­73.
[8] Kim YM, Kols A, Muchele S. Informed choice and decision-making in family planning counseling in Kenya. Int Fam Plan Perspect 1998;24(1):4.
[9] Koenig MA, Hossain MB, Whittaker M. The influence of quality of care upon contraception use in rural Bangladesh. Stud Fam Plann 1997;28(4):278­89.
[10] Feijoo AR, León FR, Ochoa L, Padilla A, Roca ST, Ríos A. One­year client impacts of quality of care improvements achieved in Peru [Internet]. [Internet]. Population Council; 2004. (Frontiers in Reproductive Health). Available from: http://pdf.usaid.gov/pdf_docs/PNACW582.pdf.
[11] Jain AK, Ramarao S, Kim J, Costello M. Evaluation of an intervention to improve quality of care in family planning programme in the Philippines. J Biosoc Sci 2012;44(1): 27–41.
[12] Svin I, Stern J, Coutinho E, Mattos CFR, El Mahgoub S, Díaz S, et al. Prolonged intra­uterine contraception: a seven­year randomized study of the levonorgestrel 20 mcg/day (LNG 20) and the copper T380 at JUIJS. Contraception 1991;44(5):473–80.
[13] Fleming D, Davie J, Glasier A. Continuation rates of long­acting methods of contraception: a comparative study of Norplant® implants and intrauterine devices. Con­traception 1998;57(1):19­21.
[14] Deans EI, Grimes DA. Intrauterine devices for adolescents: a systematic review. Con­traception 2009;79(6):418­23.
DMPA-SC. tate short cutaneous contraceptives Cameron Raifman of (DMPA) Study Jacobs Inst. Women’s Health 2018;28(1):68–74. https://doi.org/10.1016/j.whi. 2017.07.006.

[15] Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMFCA-SC. Contraception 2004;70(4):269–75.

[16] Spieler J. Sayan® press: can it be a “game changer” for reducing unmet need for family planning? Contraception 2014;89(5):335–8.

[17] Cover J, Namagamba A, Tumusime J, Lim J, Drake JK, Mbone AK. A Prospective Co-hort Study of the Feasibility and Acceptability of Depot Medroxyprogesterone Acetate (DMPA) Administered Subcutaneously through Self-injection. Contraception 2017;95:306–11.

[18] Cameron ST, Glasier A, Johnstone A. Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception. Contraception 2012;85(5):458–64.

[19] Cover J, Namagamba A, Tumusime J, Nsangi D, Lim J, Nakiganda-Busiku D. Continuation of injectable contraception when self-injected vs. administered by a facility-based health worker: A non-randomized, prospective cohort study in Uganda. Contraception 2018;98:383–8.

[20] Burke HM, Chen M, Buluzzi M, Fuchs R, Wovell S, Venkatasubramanian L, et al. Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial. Lancet Glob Health 2018;6(5):e568–78.

[21] Ross JA, Agwanda AT. Increased use of injectable contraception in sub-Saharan Africa. Afr J Reprod Health 2012 Dec;16(4):68–80.

[22] Ross J, Hardee K. Access to contraceptive methods and prevalence of use. J Biosoc Sci 2013 Nov;45(6):761–78.

[23] Ross J, Keesbury J, Hardee K. Trends in the contraceptive method mix in low- and middle-income countries: analysis using a new “average deviation” measure. Glob Health Sci Pract 2015;3(1):34–55.

[24] Dennis ML, Radovick E, Wong KLM, Owolabi O, Cavallaro FL, Mhizvo MT, et al. Pathways to increased coverage: an analysis of time trends in contraceptive need and use among adolescents and young women in Kenya, Rwanda, Tanzania, and Uganda. Reprod Health 2017;14(1):130.

[25] Hubacher D, Cocco N, Gonzalez B, Taylor D. Factors affecting continuation rates of DMPA. Contraception 1999;60(6):345–51.

[26] Tolley E, Loza S, Kafal L, Cummings S. The impact of menstrual side effects on contraceptive discontinuation: findings from a longitudinal study in Cairo, Egypt. Int Fam Plan Perspect 2005;31(1):15–23.

[27] Westfall JM, Main DS, Barnard L. Continuation rates among injectable contraceptive users. Fam Plann Perspect 1996;28(6):275–7.

[28] Paul C, Skegg DC, Williams S. Depot medroxyprogesterone acetate. Patterns of use and reasons for discontinuation. Contraception 1997;56(4):209–14.

[29] Hu E, Ikealco LC, Obiora-Okafor NC. The use of depot medroxyprogesterone acetate (DMPA) injectable contraceptive in Enugu, Nigeria. Niger J Med J Natl Assoc Resid Dr Niger 2012;21(3):266–71.

[30] Kohn JE, Simons HR, Della Badia L, Draper E, Morfesis J, Talmont E, et al. Increased 1-year continuation of DMPA among women randomized to self-administration: results from a randomized controlled trial at Planned Parenthood. Contraception 2018;97(3):198–204.

[31] Baumgartner JN, Morrone C, Mtabladi RD, Otterness C, Buga G, Chen M. Impact of a provider job aid intervention on injectable contraceptive continuation in South Africa. Stud Fam Plann 2012;43(4):305–14.

[32] Lei Z-W, Wu SC, Garceau RJ, Jiang S, Yang Q-Z, Wang W-L, et al. Effect of pretreatment counseling on discontinuation rates in Chinese women given depot-medroxyprogesterone acetate for contraception. Contraception 1996;53(3):357–61.

[33] Cetina TEOC, Canto P, Luna MO. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. Contraception 2001;63 (3):143–6.

[34] National Population Commission (NPC) [Nigeria], ICF International. Nigeria Demographic and Health Survey 2013. Abuja, Nigeria, and Rockville, Maryland, USA: National Population Commission (NPC) [Nigeria] and ICF International; 2014.

[35] Liu Jenny, Schatzkin Eric, Omoluabi F, Fajemisin M, Osumo C, Erinsolami T, et al. Introducing the subcutaneous depot medroxyprogesterone acetate injectable contraceptive via social marketing: Lessons learned from Nigeria’s private sector; 2018.

[36] Bruce J. Fundamental elements of the quality of care: a simple framework. Stud Fam Plann 1990;21(2):61–91.

[37] Afuah J, Diamond-Smith N, Golub G, Sudhin araset M. Development of a tool to measure person-centered maternity care in developing settings: validation in a rural and urban Kenyan population. Reprod Health Sep 22 2017;14(1):118. https://doi.org/10.1186/s12978-017-0381-7.

[38] Prata N, Gessessew A, Cartwright A, Fraser A. Provision of injectable contraceptives in Ethiopia through community-based reproductive health agents. Bull World Health Organ 2011;89(6):556–64.

[39] MEASURE Evaluation. Quick Investigation of Quality: A User’s Guide for Monitoring Quality of Care in Family Planning (2nd Ed.). Chapel Hill, North Carolina: MEASURE Evaluation, University of North Carolina; 2016 Available from: https://www.measureevaluation.org/resources/publications/ms-15-104.

[40] Dehlerdorf C, Krajewski C, Borroto S. Contraceptive counseling: best practices to ensure quality communication and enable effective contraceptive use. Clin Obstet Gynecol 2014;57(4):659–73.

[41] Ojikutu B, Higgins-Biddle M, Greeson D, Phelps BR, Amzel A, Okechukwu E, et al. The association between quality of HIV care, loss to follow-up and mortality in pediatric and adolescent patients receiving antiretroviral therapy in Nigeria. PloS One 2014;9(7):e100039.

[42] Chakraborty NM, Firestone R, Bellows N. Equity monitoring for social marketing: use of wealth quintiles and the concentration index for decision making in HIV prevention, family planning, and malaria programs. MC Public Health 2013;13(36).

[43] Dehlerdorff C, Levy K, Kelley A, Grumbach K, Steinauer J. Women’s preferences for contraceptive counseling and decision making. Contraception 2013;88(2): 250–6.

[44] Adeyemi AS, Adekanle DA. Progestogen-only injectable contraceptive: Experience of women in Osogbo, southwestern Nigeria. Ann Afr Med 2012;11(1):27–31.

[45] Hubacher D, Lopez I, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception 2009 Aug;80(2):113–8.

[46] Diamond-Smith N, Treleaven E, Omoluabi E, Liu J. Comparing simulated client experiences with and phone survey self-reports for measuring the quality of family planning counseling: The case of DMPA-SC in Nigeria; 2017.